• Pentavere continues to publish ground-breaking AI work accepted at prestigious global medical conferences and leading oncology organizations. In the past quarter Pentavere presented its AI work, in partnership with leading academic centers and global pharmaceutical companies at a number of prestigious conferences.
  
• In a recent report focused on AI in Health⁽¹⁾, The Organization for Economic Cooperation and Development (OECD) referenced the work of two scientific researchers⁽²⁾ who leveraged Pentavere’s technology to draw conclusions that AI can help health professionals provide more time to care and improve quality of outcomes.

TORONTO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- HEALWELL AI Inc. (“HEALWELL” or the “Company”) (TSX: AIDX) (OTCQX: HWAIF), an AI and data science company focused on preventative care, is pleased to announce that its subsidiary Pentavere Research Group Inc. (“Pentavere”), continues to publish ground-breaking AI work accepted at prestigious global medical conferences and leading oncology organizations. In the past quarter Pentavere has presented its AI work, in partnership with leading academic centers and global pharmaceutical companies at the following prestigious conferences:

• AACR: Advances in Breast Cancer Research in San Diego. Real-world treatment patterns and clinical outcomes in patients with HER2+ metastatic breast cancer receiving systemic therapy.
• The International Consensus Conference for Advanced in Breast Cancer in Lisbon. Treatment Patterns and Clinical Outcomes Among Patients Receiving CDK4/6 Inhibitors for HR+/HER2- Advanced/Metastatic Breast Cancer in a Single-Centre, Canadian Real-World Setting Using AI-Extracted Data.
• North American Conference on Lung Cancer in Chicago. Real-world outcomes of patients with advanced EGFR-mutated NSCLC in Canada using AI-extracted data.
• Accepted for podium presentation at the upcoming American Head and Neck Society Meeting in Chicago. Using Artificial Intelligence to automate the extraction of staging criteria from the electronic health records of oropharyngeal cancer patient.

Also, in a recent report focused on AI in Health⁽¹⁾, The Organization for Economic Cooperation and Development (OECD) referenced the work of two scientific researchers⁽²⁾ who leveraged Pentavere’s DARWEN™ technology to draw conclusions that AI can improve quality of work and health outcomes.

The works cited by the study indicated, “AI can help providers integrate leading knowledge and mine health data to find critical signals to prevent patients falling between the cracks and improve adherence to clinical leading practice.” These works were used to draw conclusions that AI can help health professionals provide more time to care and improve quality of outcomes.

Aaron Leibtag, Co-Founder and CEO of Pentavere commented, “The scientific medical community is increasingly recognizing the power and promise of AI to help drive significant improvements in preventative care and patient outcomes. Our DARWEN™ technology platform enables doctors to utilize data that already exists and unlock knowledge buried in millions of pages of clinical information. We are committed to demonstrating how AI can help clinicians better understand patient populations, optimize the course of treatment and ultimately improve patient outcomes.”

Dr. Christopher Pettengell, Pentavere’s Chief Medical Officer noted that, “Accurate and timely diagnosis and staging to determine if a patient is a candidate for precision medicines is critical for treatment and the work we have recently published shows the potential of AI to support clinicians and enhance patient care. The use of validated AI technologies such as Pentavere’s DARWEN™ allow clinicians to efficiently identify patients and access previously unavailable real-world data⁽³⁾.”

DARWEN™, Pentavere’s AI engine, unlocks a deeper understanding of patient treatment needs by enabling effortless data access and rapid insight generation. DARWEN™ harnesses EMR data and utilizes advanced large language models to analyze disparate and siloed clinical notes that are otherwise very challenging to access, allowing meaningful solutions to some of healthcare’s biggest challenges and delivering on the current need for medicine to become more personalized.

Dr. Alexander Dobranowski
Chief Executive Officer
HEALWELL AI Inc.

Footnotes:
(1) https://www.oecd.org/health/AI-in-health-huge-potential-huge-risks.pdf
(2) Vender, R. and C. Lynde (2023), “AI-Powered Patient Identification to Optimse Care”, Click here to access the source.
(3) Moulson R, Feugère G,Moreira-Lucas TS, Dequen F, Weiss J, Smith J, Brezden-Masley C. Treatment Patterns and Clinical Outcomes Among Patients Receiving CDK4/6 Inhibitors for HR+/HER2- Advanced/Metastatic Breast Cancer in a Single-Centre, Canadian Real-World Setting Using AI-Extracted Data. The International Consensus Conference for Advanced in Breast Cancer; 2023 Nov 9-11; Lisbon, Portugal.

About HEALWELL AI

HEALWELL AI is a healthcare technology company focused on AI and data science for preventative care. Its mission is to improve health care and save lives through early identification and detection of disease. As a physician-led organization with a proven management team of experienced executives, HEALWELL AI is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol “AIDX” and on the OTC Exchange under the symbol “HWAIF”. To learn more about HEALWELL AI, please visit: https://healwell.ai/.

About Pentavere

Pentavere Research Group is a globally recognized and award-winning AI digital health company that has built a best-in-class AI engine to identify patients that are eligible for approved medications or interventions, to improve outcomes for patients and help drive therapy growth and penetration. Pentavere's AI system, DARWEN™, identifies patients that are eligible for but not receiving approved medications or interventions, improving outcomes for patients and helping drive appropriate therapy growth and penetration.

Forward Looking Statements

Certain statements in this press release, constitute "forward-looking information" and "forward looking statements" (collectively, "forward looking statements") within the meaning of applicable Canadian securities laws and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements in this press release include statements with respect to, among other things: the DARWEN platform will improve patient outcomes, Forward-looking statements are often, but not always, identified by words or phrases such as "to become", "improve", "growth", "ensuring", "continue", "anticipated", "expects", "proceed", "potential", "future", "consider", "result in", "increase", "deliver", "emerging", “is poised”, "plan", "position", "opportunities", "expansion", "exercise", "ensure", "achieve", "acquire", "complete", "satisfy", "entitle", "subject to" or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can" be taken, occur or be achieved, or the negative of any of these terms. Forward-looking statements are necessarily based upon management’s perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: the stability of general economic and market conditions; HEALWELL's ability to comply with applicable laws and regulations; HEALWELL's continued compliance with third party intellectual property rights; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.

Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in HEALWELL's most recent annual information form dated March 31, 2023, which is available under HEALWELL's SEDAR+ profile at www.sedarplus.ca. The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.

For more information:

Aaron Leibtag
CEO, Pentavere
This email address is being protected from spambots. You need JavaScript enabled to view it.

Pardeep S. Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392
This email address is being protected from spambots. You need JavaScript enabled to view it.